AgomAb Therapeutics (NASDAQ:AGMB) Shares Down 5.9% – Here’s Why

AgomAb Therapeutics NV (NASDAQ:AGMB) fell 5.9% during trading on Wednesday . The stock traded as low as $13.80 and last traded at $13.98. Approximately 128,480 shares were traded during mid-day trading, a decline of 2% from the average daily volume of 130,966 shares. The stock had previously closed at $14.85.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. HC Wainwright initiated coverage on AgomAb Therapeutics in a research note on Monday, June 22nd. They set a “buy” rating and a $35.00 price target on the stock. B. Riley Financial started coverage on AgomAb Therapeutics in a research report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price objective for the company. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $33.00.

AgomAb Therapeutics Trading Down 0.9%

The firm has a 50-day moving average of $12.46.

AgomAb Therapeutics (NASDAQ:AGMB) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. On average, equities research analysts expect that AgomAb Therapeutics NV will post -1.74 earnings per share for the current year.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.